Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinoma

24 Sept 2018

Abstract excerpt

Accurately identifying patients with high-grade serous ovarian carcinoma (HGSOC) who respond to poly(ADP-ribose) polymerase inhibitor (PARPi) therapy is of great clinical importance. Here we show that quantitative BRCA1 methylation analysis provides new insight into PARPi response in preclinical models and ovarian cancer patients. The response of 12 HGSOC patient-derived xenografts (PDX) to the PARPi rucaparib...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to DNA Repair Mechanisms
Share to Ovarian cancer diagnosis and treatment
Share to PARP inhibition in cancer therapy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 30266954
DOI: 10.1038/s41467-018-05564-z

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinomaPMID 30266954Read ↗

Genomic alterations enable <i>BRCA1</i> methylation loss and promoter bypass to drive resistance in high-grade serous ovarian cancerSemantic proximity Read ↗

Acquired RAD51C Promoter Methylation Loss Causes PARP Inhibitor Resistance in High-Grade Serous Ovarian CarcinomaSemantic proximity Read ↗

Acquired <i>RAD51C</i> promoter methylation loss causes PARP inhibitor resistance in high grade serous ovarian carcinomaSemantic proximity Read ↗

Demethylating agents drive PARP inhibitor resistance in ovarian carcinomas with BRCA1 gene silencingSemantic proximity Read ↗

Characterization of a RAD51C -silenced high-grade serous ovarian cancer model during development of PARP inhibitor resistanceSemantic proximity Read ↗

Clinical utility of HRR gene methylation for predicting PARPi sensitivity in HGSOC patientsSemantic proximity Read ↗

Targeting BRPF3 moderately reverses olaparib resistance in high grade serous ovarian carcinomaSemantic proximity Read ↗

Genome-wide methylation profiling of ovarian cancer patient-derived xenografts treated with the demethylating agent decitabine identifies novel epigenetically regulated genes and pathwaysSemantic proximity Read ↗

Generation of a PARPi-sensitive homozygous BRCA1-methylated OVCAR8 cell line using targeted CRISPR gene editingSemantic proximity Read ↗

Histone methyltransferases EHMT1 and EHMT2 (GLP/G9A) maintain PARP inhibitor resistance in high-grade serous ovarian carcinomaSemantic proximity Read ↗

PARP inhibitors in ovarian cancer: Mechanisms of resistance and implications to therapySemantic proximity Read ↗

BRCA Methylation Testing Identifies a Subset of Ovarian Carcinomas without Germline Variants That Can Benefit from PARP Inhibitor.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.